Quantum Biopharma (QNTM) & Its Rivals Head to Head Survey

Institutional and Insider Ownership

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 8.5% of Quantum Biopharma shares are held by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Quantum Biopharma and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Quantum Biopharma	N/A	-$17.90 million	-0.21
Quantum Biopharma Competitors	$2.15 billion	$158.33 million	-5.99

Quantum Biopharma’s rivals have higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Quantum Biopharma has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Quantum Biopharma’s rivals have a beta of 3.88, suggesting that their average stock price is 288% more volatile than the S&P 500.

Profitability

This table compares Quantum Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-84.21%	-62.63%
Quantum Biopharma Competitors	-3,419.56%	-220.74%	-32.93%

Summary

Quantum Biopharma rivals beat Quantum Biopharma on 6 of the 9 factors compared.

About Quantum Biopharma

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.